We present the case of a 52-year-old woman who developed a functional small bowel obstruction despite having no history of abdominal surgery, prior bowel obstruction, or GI interventions. The only notable recent change in her medical history was a dose escalation of Zepbound (tirzepatide), a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonist prescribed for weight loss. This case raises concern about potential severe GI motility complications associated with Zepbound, particularly in the absence of conventional SBO risk factors.